Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
ELEVAI Labs Inc. ( (ELAB) ) has issued an announcement.
On May 12, 2025, Northstrive Biosciences Inc. entered into a Second Amendment to its License Agreement with MOA Life Plus Co., Ltd., clarifying the application of certain provisions related to animal health. This amendment limits Northstrive’s payment obligations to royalties on net sales and sublicensing revenues in the animal health field. Additionally, Northstrive signed a binding term sheet with Modulant Biosciences LLC for a future licensing agreement, granting Modulant exclusive global rights to develop and commercialize EL-22 for animal health, excluding Korea. This collaboration aims to monetize EL-22’s intellectual property and could become a significant revenue-generating asset for Northstrive if successfully developed and marketed.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Underperform.
ELEVAI Labs Inc. is rated poorly due to major financial weaknesses, including negative revenue and cash flow issues, which are exacerbated by adverse technical indicators. The lack of favorable valuation metrics further weighs down the stock’s score. The absence of applicable corporate events means no positive catalysts are present to offset these challenges.
To see Spark’s full report on ELAB stock, click here.
More about ELEVAI Labs Inc.
Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., is a biopharmaceutical company that focuses on developing and acquiring innovative aesthetic medicines. Its lead asset, EL-22, utilizes an engineered probiotic approach to address muscle preservation during weight loss treatments. PMGC Holdings Inc. is a diversified holding company with a portfolio that includes Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC, aiming to maximize growth through strategic acquisitions and investments.
Average Trading Volume: 619,931
Technical Sentiment Signal: Sell
Current Market Cap: $2.2M
Find detailed analytics on ELAB stock on TipRanks’ Stock Analysis page.